Ionis reports first quarter 2020 financial results and recent business achievements
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St set for higher open as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Ionis Pharmaceuticals (IONS) Misses Q1 EPS by 23c
May 6, 2020 7:14 AM EDTIonis Pharmaceuticals (NASDAQ: IONS) reported Q1 EPS of ($0.35), $0.23 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $133 million versus the consensus estimate of $161.13 million.
On track to achieve 2020 financial guidance"We are reaffirming our 2020 financial guidance, including... More